 Combined Company Will Operate as Biosight Therapeutics to Advance Pipeline of Clinical-Stage Oncology Programs with Lead Program Aspacytarabine BST-236 in Acute Myeloid Leukemia AML and Myelodysplastic Syndrome MDS 